Optum guides members and providers through important upcoming formulary updates. See multiple tabs of linked spreadsheet for Select, Premium & UM Changes.
Egaten™ (triclabendazole) – New orphan drug approval
February 13, 2019 - Novartis announced the FDA approval of Egaten (triclabendazole), for the treatment of fascioliasis in patients 6 years of age and older.
